Moreover, patients with PP2A phosphorylation/inhibition had significantly worse clinical outcome and multivariate analysis, suggesting that PP2A phosphorylation/inhibition has an independent prognostic value for overall and event-free survival in breast cancer patients. This evidence concerns the gene PTPA and breast carcinoma.